Roth Capital Resumes BioLineRx (BLRX) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Roth Reinstates BioLineRx (BLRX) at 'Buy'; Strong Pipeline Reinforces Upside Potential
July 2, 2014 9:27 AM EDTRoth Capital reinstates BioLineRx Ltd. (Nasdaq: BLRX) with a Buy rating and price target of $8.
Analust Joseph Pantginis issued the following commentary with the reinstatement, We believe BioLineRx is poised for growth based on a deep pipeline, risk mitigation through its early partnering business model, and partnering validation based on multiple partnerships already in hand. We believe BioLineRx has the ability to maintain a... More
